SuperworthUnited Therapeutics profit margin UTHR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 41.6%
- Operating margin, 12 months
- 44.4%
- Net margin on a year earlier
- +1.2 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, United Therapeutics kept 41.6% of its revenue as net profit, with an operating margin of 44.4% and a gross margin of 86.1%.
Five years earlier its net margin was 29.6%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 41.9% | 46.9% | 87.9% |
| FY2024 | 41.5% | 47.9% | 89.2% |
| FY2023 | 42.3% | 50.9% | 88.9% |
| FY2022 | 37.6% | 50.6% | 92.2% |
| FY2021 | 28.2% | 33.0% | 92.7% |
| FY2020 | 34.7% | 40.0% | 92.7% |
| FY2019 | −7.2% | −12.9% | 91.9% |
| FY2018 | 36.2% | 49.5% | 87.8% |
| FY2017 | 24.2% | 47.2% | 93.9% |
| FY2016 | 44.6% | 66.4% | 95.5% |
| FY2015 | 44.5% | 47.7% | 95.3% |
| FY2014 | 26.4% | 41.8% | 90.2% |
| FY2013 | 15.6% | 26.2% | 88.3% |
| FY2012 | 33.2% | 46.0% | 87.0% |
| FY2011 | 29.3% | 42.8% | 88.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 41.6% | +1.2 pts | 44.4% | |
| Q1 FY26 | 40.6% | +0.2 pts | 45.3% | |
| Q4 FY25 | 41.9% | +0.4 pts | 46.9% | |
| Q3 FY25 | 40.7% | +0.3 pts | 47.7% | |
| Q2 FY25 | 40.4% | −0.5 pts | 47.0% | |
| Q1 FY25 | 40.4% | −1.6 pts | 46.9% | |
| Q4 FY24 | 41.5% | −0.8 pts | 47.9% | |
| Q3 FY24 | 40.3% | −0.5 pts | 46.4% | |
| Q2 FY24 | 40.9% | −0.4 pts | 48.3% | |
| Q1 FY24 | 42.0% | +5.3 pts | 50.3% | |
| Q4 FY23 | 42.3% | +4.8 pts | 50.9% | |
| Q3 FY23 | 40.8% | +2.8 pts | 49.9% |
Against its peers
Companies in Biotechnology nearest United Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| UTHRUnited Therapeutics | 41.6% |
| INCYIncyte | 27.7% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| EXELExelixis | 35.3% |
| ONCBeOne Medicines | 10.7% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| Peer median | 22.9% |
Where United Therapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on United Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.